IDEXX Laboratories, Inc. (IDXX)
USD 410.76
(-3.82%)
USD 410.76
(-3.82%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 845.04 Million USD | 24.44% |
| 2022 | 679.08 Million USD | -8.83% |
| 2021 | 744.84 Million USD | 28.03% |
| 2020 | 581.77 Million USD | 36.02% |
| 2019 | 427.72 Million USD | 13.44% |
| 2018 | 377.03 Million USD | 43.28% |
| 2017 | 263.14 Million USD | 18.51% |
| 2016 | 222.04 Million USD | 15.6% |
| 2015 | 192.07 Million USD | 5.59% |
| 2014 | 181.9 Million USD | -3.14% |
| 2013 | 187.8 Million USD | 5.35% |
| 2012 | 178.26 Million USD | 10.19% |
| 2011 | 161.78 Million USD | 14.51% |
| 2010 | 141.28 Million USD | 15.59% |
| 2009 | 122.22 Million USD | 5.21% |
| 2008 | 116.16 Million USD | 23.57% |
| 2007 | 94.01 Million USD | 0.36% |
| 2006 | 93.67 Million USD | 19.71% |
| 2005 | 78.25 Million USD | -0.1% |
| 2004 | 78.33 Million USD | 37.21% |
| 2003 | 57.09 Million USD | 25.78% |
| 2002 | 45.38 Million USD | 20.65% |
| 2001 | 37.62 Million USD | 2.7% |
| 2000 | 36.63 Million USD | 12.37% |
| 1999 | 32.6 Million USD | 314.47% |
| 1998 | -15.2 Million USD | 27.96% |
| 1997 | -21.1 Million USD | -164.72% |
| 1996 | 32.6 Million USD | 51.63% |
| 1995 | 21.5 Million USD | 61.65% |
| 1994 | 13.3 Million USD | 37.11% |
| 1993 | 9.7 Million USD | 97.96% |
| 1992 | 4.9 Million USD | 53.13% |
| 1991 | 3.2 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 235.57 Million USD | 21.11% |
| 2024 Q2 | 203.29 Million USD | -13.7% |
| 2024 Q3 | 232.84 Million USD | 14.53% |
| 2023 Q3 | 212.23 Million USD | -5.35% |
| 2023 Q2 | 224.23 Million USD | 4.76% |
| 2023 Q1 | 214.05 Million USD | 24.3% |
| 2023 FY | 845.04 Million USD | 24.44% |
| 2023 Q4 | 194.52 Million USD | -8.34% |
| 2022 Q3 | 180.93 Million USD | 37.1% |
| 2022 Q1 | 193.96 Million USD | 19.16% |
| 2022 Q2 | 131.97 Million USD | -31.96% |
| 2022 FY | 679.08 Million USD | -8.83% |
| 2022 Q4 | 172.2 Million USD | -4.83% |
| 2021 Q4 | 162.77 Million USD | -7.11% |
| 2021 Q1 | 204.25 Million USD | 16.86% |
| 2021 Q2 | 202.58 Million USD | -0.82% |
| 2021 Q3 | 175.23 Million USD | -13.5% |
| 2021 FY | 744.84 Million USD | 28.03% |
| 2020 Q4 | 174.79 Million USD | 19.54% |
| 2020 Q1 | 111.82 Million USD | 23.57% |
| 2020 FY | 581.77 Million USD | 36.02% |
| 2020 Q2 | 148.94 Million USD | 33.19% |
| 2020 Q3 | 146.21 Million USD | -1.83% |
| 2019 Q1 | 102.68 Million USD | 19.9% |
| 2019 FY | 427.72 Million USD | 13.44% |
| 2019 Q4 | 90.49 Million USD | -16.85% |
| 2019 Q3 | 108.83 Million USD | -13.42% |
| 2019 Q2 | 125.7 Million USD | 22.42% |
| 2018 Q4 | 85.63 Million USD | -8.16% |
| 2018 FY | 377.03 Million USD | 43.28% |
| 2018 Q2 | 108.69 Million USD | 21.51% |
| 2018 Q1 | 89.45 Million USD | 133.82% |
| 2018 Q3 | 93.25 Million USD | -14.21% |
| 2017 Q1 | 69.01 Million USD | 31.79% |
| 2017 FY | 263.14 Million USD | 18.51% |
| 2017 Q4 | 38.25 Million USD | -45.74% |
| 2017 Q2 | 85.35 Million USD | 23.67% |
| 2017 Q3 | 70.51 Million USD | -17.39% |
| 2016 Q1 | 46.01 Million USD | 3.77% |
| 2016 FY | 222.04 Million USD | 15.6% |
| 2016 Q4 | 52.36 Million USD | -7.24% |
| 2016 Q3 | 56.45 Million USD | -15.99% |
| 2016 Q2 | 67.2 Million USD | 46.03% |
| 2015 Q3 | 44.22 Million USD | -22.3% |
| 2015 FY | 192.07 Million USD | 5.59% |
| 2015 Q1 | 46.59 Million USD | 79.48% |
| 2015 Q2 | 56.91 Million USD | 22.14% |
| 2015 Q4 | 44.34 Million USD | 0.28% |
| 2014 Q3 | 52.14 Million USD | -8.87% |
| 2014 Q1 | 46.58 Million USD | 7.69% |
| 2014 FY | 181.9 Million USD | -3.14% |
| 2014 Q2 | 57.21 Million USD | 22.82% |
| 2014 Q4 | 25.96 Million USD | -50.21% |
| 2013 Q1 | 44.86 Million USD | 3.47% |
| 2013 FY | 187.8 Million USD | 5.35% |
| 2013 Q4 | 43.25 Million USD | -5.32% |
| 2013 Q3 | 45.68 Million USD | -15.38% |
| 2013 Q2 | 53.99 Million USD | 20.36% |
| 2012 Q3 | 42.85 Million USD | -16.49% |
| 2012 Q2 | 51.31 Million USD | 25.95% |
| 2012 Q1 | 40.74 Million USD | 7.19% |
| 2012 FY | 178.26 Million USD | 10.19% |
| 2012 Q4 | 43.35 Million USD | 1.17% |
| 2011 Q4 | 38.01 Million USD | -1.29% |
| 2011 FY | 161.78 Million USD | 14.51% |
| 2011 Q1 | 36.61 Million USD | 0.66% |
| 2011 Q2 | 48.65 Million USD | 32.9% |
| 2011 Q3 | 38.5 Million USD | -20.86% |
| 2010 FY | 141.28 Million USD | 15.59% |
| 2010 Q4 | 36.37 Million USD | 4.83% |
| 2010 Q3 | 34.69 Million USD | -6.72% |
| 2010 Q2 | 37.19 Million USD | 12.62% |
| 2010 Q1 | 33.02 Million USD | 6.7% |
| 2009 FY | 122.22 Million USD | 5.21% |
| 2009 Q3 | 31.53 Million USD | -6.33% |
| 2009 Q2 | 33.66 Million USD | 29.14% |
| 2009 Q1 | 26.07 Million USD | 10.68% |
| 2009 Q4 | 30.95 Million USD | -1.86% |
| 2008 FY | 116.16 Million USD | 23.57% |
| 2008 Q3 | 25.69 Million USD | -34.71% |
| 2008 Q2 | 39.36 Million USD | 42.88% |
| 2008 Q4 | 23.55 Million USD | -8.34% |
| 2008 Q1 | 27.55 Million USD | 7.92% |
| 2007 Q3 | 25.79 Million USD | 19.07% |
| 2007 Q2 | 21.66 Million USD | 3.03% |
| 2007 Q1 | 21.02 Million USD | -14.77% |
| 2007 FY | 94.01 Million USD | 0.36% |
| 2007 Q4 | 25.52 Million USD | -1.04% |
| 2006 FY | 93.67 Million USD | 19.71% |
| 2006 Q4 | 24.67 Million USD | -1.13% |
| 2006 Q3 | 24.95 Million USD | -3.21% |
| 2006 Q2 | 25.78 Million USD | 41.08% |
| 2006 Q1 | 18.27 Million USD | -8.76% |
| 2005 Q1 | 17.69 Million USD | 4.46% |
| 2005 FY | 78.25 Million USD | -0.1% |
| 2005 Q4 | 20.02 Million USD | -2.8% |
| 2005 Q3 | 20.6 Million USD | 3.37% |
| 2005 Q2 | 19.93 Million USD | 12.68% |
| 2004 Q2 | 23.91 Million USD | 34.39% |
| 2004 Q3 | 19.69 Million USD | -17.62% |
| 2004 Q4 | 16.93 Million USD | -14.02% |
| 2004 FY | 78.33 Million USD | 37.21% |
| 2004 Q1 | 17.79 Million USD | 43.88% |
| 2003 Q2 | 16.69 Million USD | 38.37% |
| 2003 Q1 | 12.06 Million USD | -5.45% |
| 2003 Q3 | 15.97 Million USD | -4.3% |
| 2003 Q4 | 12.36 Million USD | -22.59% |
| 2003 FY | 57.09 Million USD | 25.78% |
| 2002 Q4 | 12.75 Million USD | 2.19% |
| 2002 Q3 | 12.48 Million USD | -3.71% |
| 2002 Q2 | 12.96 Million USD | 80.43% |
| 2002 Q1 | 7.18 Million USD | -26.89% |
| 2002 FY | 45.38 Million USD | 20.65% |
| 2001 FY | 37.62 Million USD | 2.7% |
| 2001 Q2 | 9.96 Million USD | 30.98% |
| 2001 Q3 | 10.21 Million USD | 2.52% |
| 2001 Q4 | 9.82 Million USD | -3.81% |
| 2001 Q1 | 7.6 Million USD | -22.37% |
| 2000 Q2 | 9.52 Million USD | 18.6% |
| 2000 FY | 36.63 Million USD | 12.37% |
| 2000 Q4 | 9.8 Million USD | 5.74% |
| 2000 Q3 | 9.26 Million USD | -2.72% |
| 2000 Q1 | 8.03 Million USD | -9.73% |
| 1999 Q2 | 8 Million USD | 9.59% |
| 1999 Q3 | 8.4 Million USD | 5.0% |
| 1999 Q4 | 8.9 Million USD | 5.95% |
| 1999 FY | 32.6 Million USD | 314.47% |
| 1999 Q1 | 7.3 Million USD | 124.25% |
| 1998 Q2 | 5.1 Million USD | 34.21% |
| 1998 Q3 | 6 Million USD | 17.65% |
| 1998 Q1 | 3.8 Million USD | 222.58% |
| 1998 FY | -15.2 Million USD | 27.96% |
| 1998 Q4 | -30.1 Million USD | -601.67% |
| 1997 FY | -21.1 Million USD | -164.72% |
| 1997 Q1 | 900 Thousand USD | -90.22% |
| 1997 Q2 | -2.1 Million USD | -333.33% |
| 1997 Q3 | -16.9 Million USD | -704.76% |
| 1997 Q4 | -3.1 Million USD | 81.66% |
| 1996 FY | 32.6 Million USD | 51.63% |
| 1996 Q2 | 7.9 Million USD | 12.86% |
| 1996 Q1 | 7 Million USD | -1.41% |
| 1996 Q4 | 9.2 Million USD | 6.98% |
| 1996 Q3 | 8.6 Million USD | 8.86% |
| 1995 Q3 | 5.4 Million USD | 10.2% |
| 1995 Q4 | 7.1 Million USD | 31.48% |
| 1995 FY | 21.5 Million USD | 61.65% |
| 1995 Q1 | 4 Million USD | -6.98% |
| 1995 Q2 | 4.9 Million USD | 22.5% |
| 1994 Q2 | 2.6 Million USD | -7.14% |
| 1994 Q3 | 3.6 Million USD | 38.46% |
| 1994 Q4 | 4.3 Million USD | 19.44% |
| 1994 FY | 13.3 Million USD | 37.11% |
| 1994 Q1 | 2.8 Million USD | -24.32% |
| 1993 FY | 9.7 Million USD | 97.96% |
| 1993 Q2 | 2.1 Million USD | 50.0% |
| 1993 Q4 | 3.7 Million USD | 42.31% |
| 1993 Q1 | 1.4 Million USD | -17.65% |
| 1993 Q3 | 2.6 Million USD | 23.81% |
| 1992 Q1 | 500 Thousand USD | -61.54% |
| 1992 Q4 | 1.7 Million USD | 13.33% |
| 1992 Q3 | 1.5 Million USD | 25.0% |
| 1992 FY | 4.9 Million USD | 53.13% |
| 1992 Q2 | 1.2 Million USD | 140.0% |
| 1991 Q1 | - USD | 0.0% |
| 1991 FY | 3.2 Million USD | 0.0% |
| 1991 Q3 | 1 Million USD | 66.67% |
| 1991 Q2 | 600 Thousand USD | 0.0% |
| 1991 Q4 | 1.3 Million USD | 30.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 463.47% |
| Prenetics Global Limited | -62.72 Million USD | 1447.241% |
| Star Equity Holdings, Inc. | -1.54 Million USD | 54689.276% |
| CareDx, Inc | -190.28 Million USD | 544.095% |
| Exact Sciences Corporation | -204.14 Million USD | 513.934% |
| Exagen Inc. | -23.68 Million USD | 3667.234% |
| Inotiv, Inc. | -105.14 Million USD | 903.73% |
| Guardant Health, Inc. | -479.44 Million USD | 276.253% |
| Biodesix, Inc. | -52.14 Million USD | 1720.531% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | 32242.571% |
| Precipio, Inc. | -5.85 Million USD | 14537.758% |
| iSpecimen Inc. | -11.09 Million USD | 7713.342% |
| Natera, Inc. | -434.8 Million USD | 294.351% |
| Aspira Women's Health Inc. | -16.69 Million USD | 5163.164% |
| Standard BioTools Inc. | -74.65 Million USD | 1231.914% |
| 23andMe Holding Co. | -666.7 Million USD | 226.749% |
| Castle Biosciences, Inc. | -57.46 Million USD | 1570.508% |
| Personalis, Inc. | -108.29 Million USD | 880.308% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 1055.055% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | 8595.395% |
| OpGen, Inc. | -32.66 Million USD | 2686.716% |
| T2 Biosystems, Inc. | -50.07 Million USD | 1787.485% |
| Myriad Genetics, Inc. | -112 Million USD | 854.502% |
| ICON Public Limited Company | 612.33 Million USD | -38.003% |
| NeoGenomics, Inc. | -87.96 Million USD | 1060.624% |
| Star Equity Holdings, Inc. | -1.54 Million USD | 54689.276% |
| RadNet, Inc. | 3.04 Million USD | -27660.907% |
| MDxHealth SA | -43.1 Million USD | 2060.654% |
| Psychemedics Corporation | -4.15 Million USD | 20442.85% |
| Illumina, Inc. | -1.16 Billion USD | 172.786% |
| Check-Cap Ltd. | -17.56 Million USD | 4910.121% |
| Twist Bioscience Corporation | -208.72 Million USD | 504.857% |
| DarioHealth Corp. | -59.42 Million USD | 1521.983% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 603.526% |
| Sera Prognostics, Inc. | -36.24 Million USD | 2431.665% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | 8499.811% |
| OPKO Health, Inc. | -188.86 Million USD | 547.437% |
| Medpace Holdings, Inc. | 282.81 Million USD | -198.802% |
| Neogen Corporation | -9.42 Million USD | 9069.77% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | 8419.997% |
| Prenetics Global Limited | -62.72 Million USD | 1447.241% |
| Mainz Biomed B.V. | -26.29 Million USD | 3313.61% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | 10746.854% |
| Trinity Biotech plc | -24.01 Million USD | 3618.37% |
| Neuronetics, Inc. | -30.18 Million USD | 2899.172% |
| Sotera Health Company | 51.37 Million USD | -1544.819% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | 10746.854% |